Quick Answer
IRONWOOD PHARMACEUTICALS INC reported Revenue From Contract With Customer Excluding Assessed Tax of $296.15 million for the year ending 2025.
- IRONWOOD PHARMACEUTICALS INC showed a decrease of -15.7% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from IRONWOOD PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), IRONWOOD PHARMACEUTICALS INC's Revenue From Contract With Customer Excluding Assessed Tax has grown by 8.1%.
- Historical annual values: Fiscal year 2025: $296.15 million | Fiscal year 2024: $351.41 million | Fiscal year 2023: $442.74 million | Fiscal year 2022: $410.60 million | Fiscal year 2021: $413.75 million | Fiscal year 2020: $389.52 million | Fiscal year 2019: $428.41 million | Fiscal year 2018: $346.64 million | Fiscal year 2017: $298.28 million | Fiscal year 2016: $273.96 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: